文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTATATE在原发性乳腺癌中的摄取

68Ga-DOTATATE Uptake in Primary Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2021-01-01

本文报道一例74岁女性原发性心脏副神经节瘤患者,在分期PET/CT中发现乳腺68Ga-DOTATATE摄取,后续乳腺影像检查和活检证实为原发性浸润性小叶乳腺癌,而该病灶在既往18F-FDG PET/CT上无FDG摄取。该病例与既往研究一致,提示68Ga-DOTA肽未来可能在乳腺癌患者显像中发挥作用。

要点

  • 乳腺癌可表达生长抑素受体,68Ga-DOTATATE可显示摄取。
  • 本例浸润性小叶乳腺癌FDG阴性而DOTATATE阳性。
  • 68Ga-DOTA肽未来或可用于乳腺癌显像。

核心结论

  • 68Ga-DOTATATE在原发性乳腺癌中可出现摄取,且本例病灶为FDG阴性。

研究设计与样本

  • 本文为病例报告,报道一例74岁女性原发性心脏副神经节瘤患者的分期PET/CT及后续乳腺检查。

主要发现

  • 分期PET/CT显示乳腺68Ga-DOTATATE活性,后续乳腺影像和活检证实为原发性浸润性小叶乳腺癌。
  • 该乳腺癌病灶在既往18F-FDG PET/CT上无FDG摄取。

临床怎么用

  • 对已知可表达生长抑素受体的肿瘤患者,68Ga-DOTATATE显像发现乳腺摄取时应进一步行乳腺影像和活检明确。

局限性

  • 本文为单例病例报告,不能推断68Ga-DOTA肽在乳腺癌显像中的普遍适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-DOTA peptides have revolutionized the imaging of neuroendocrine tumors because the agents are specific to somatostatin receptors. However, other tumors, including breast cancer, have been shown to express somatostatin receptors. We present the case of a 74-year-old woman with primary cardiac paraganglioma, who was found to have 68Ga-DOTATATE activity in the breast on staging PET/CT. Subsequent breast imaging workup and biopsy confirmed primary invasive lobular breast cancer, which was not 18F-FDG-avid on prior FDG PET/CT. Our case is in alignment with prior studies that suggest that 68Ga-DOTA peptides may play a future role in imaging breast cancer patients.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Guirguis MS, Adrada BE, Surasi DS, et al. 68Ga-DOTATATE Uptake in Primary Breast Cancer. Clin Nucl Med. 2021. PMID: 33234932. doi:10.1097/RLU.0000000000003421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。